Glenn Goddard Intellia Therapeutics, Inc. (NTLA) insider trading activity

Glenn Goddard is EVP, Chief Financial Officer of Intellia Therapeutics, Inc.. Currently has a direct ownership of 69,213 shares of NTLA, which is worth approximately $989,745. The most recent transaction as insider was on Mar 01, 2024, when has been sold 28,628 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 69.2K

0% 3M change

61.38% 12M change

Total Value Held $989,745

Glenn Goddard Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 01 2024	BUY Grant, award, or other acquisition	-	28,628 Added 29.26%	69,213 Common Stock
Jan 03 2024	SELL Open market or private sale	$158,052 $29.46 p/Share	5,365 Reduced 11.68%	40,585 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	3,062 Added 6.25%	45,950 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	27,484 Added 39.06%	42,888 Common Stock
Jan 04 2023	SELL Open market or private sale	$90,308 $37.21 p/Share	2,427 Reduced 13.61%	15,404 Common Stock
Jan 01 2023	BUY Exercise of conversion of derivative security	-	3,062 Added 14.66%	17,831 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	12,720 Added 46.27%	14,769 Common Stock
Jan 01 2022	SELL Open market or private sale	$113,699 $112.24 p/Share	1,013 Reduced 33.08%	2,049 Common Stock
Jan 01 2022	BUY Exercise of conversion of derivative security	-	3,062 Added 50.0%	3,062 Common Stock
Sep 07 2021	SELL Open market or private sale	$627,178 $180.12 p/Share	3,482 Reduced 100.0%	0 Common Stock
Sep 07 2021	BUY Exercise of conversion of derivative security	$50,768 $14.58 p/Share	3,482 Added 50.0%	3,482 Common Stock
Aug 31 2021	SELL Open market or private sale	$3,973,456 $160.22 p/Share	24,800 Reduced 100.0%	0 Common Stock
Aug 31 2021	BUY Exercise of conversion of derivative security	$419,864 $16.93 p/Share	24,800 Added 50.0%	24,800 Common Stock
Aug 30 2021	SELL Open market or private sale	$815,776 $156.88 p/Share	5,200 Reduced 100.0%	0 Common Stock
Aug 30 2021	BUY Exercise of conversion of derivative security	$100,204 $19.27 p/Share	5,200 Added 50.0%	5,200 Common Stock
Aug 05 2021	SELL Open market or private sale	$3,028,000 $151.4 p/Share	20,000 Reduced 100.0%	0 Common Stock
Aug 05 2021	BUY Exercise of conversion of derivative security	$385,400 $19.27 p/Share	20,000 Added 50.0%	20,000 Common Stock

Glenn Goddard

EVP, Chief Financial Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Value

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intellia Therapeutics, Inc.

Track Activities on NTLA

Account